Low Fitness in Midlife: A Novel Therapeutic Target for Heart Failure with Preserved Ejection Fraction Prevention
Authors:
- 1 July 2015
- journal article
- review article
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 58 (1) , 87-93
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Epidemiology of Heart Failure with Preserved Ejection FractionCurrent Heart Failure Reports, 2014
- Spironolactone for Heart Failure with Preserved Ejection FractionNew England Journal of Medicine, 2014
- Heart Disease and Stroke Statistics—2012 UpdateCirculation, 2012
- Lifetime Risks for Cardiovascular Disease Mortality by Cardiorespiratory Fitness Levels Measured at Ages 45, 55, and 65 Years in MenJACC, 2011
- Irbesartan in Patients with Heart Failure and Preserved Ejection FractionNew England Journal of Medicine, 2008
- Physical Activity and Public HealthCirculation, 2007
- Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection FractionNew England Journal of Medicine, 2006
- Outcome of Heart Failure with Preserved Ejection Fraction in a Population-Based StudyNew England Journal of Medicine, 2006
- Effect of Carvedilol on Diastolic Function in Patients with Diastolic Heart Failure and Preserved Systolic Function. Results of the Swedish Doppler-Echocardiographic Study (SWEDIC)European Journal of Heart Failure, 2004
- Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialThe Lancet, 2003